Pulmonary Nontuberculous Mycobacterial Disease, Ontario, Canada, 1998–2010

We measured the prevalence and temporal trends of pulmonary nontuberculous mycobacterial disease among residents of Ontario, Canada, during 1998–2010. Five-year prevalence increased from 29.3 cases/100,000 persons in 1998–2002 to 41.3/100,000 in 2006–2010 (p<0.0001). Improved laboratory methods did not explain this increase, suggesting a surge in disease prevalence.

[1]  K. Winthrop,et al.  Nontuberculous mycobacterial disease prevalence and risk factors: a changing epidemiology. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  Robert Horsburgh,et al.  An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. , 2007, American journal of respiratory and critical care medicine.

[3]  T. Marras,et al.  Nontuberculous Mycobacterial Lung Infections in Ontario, Canada: Clinical and Microbiological Characteristics , 2010, Lung.

[4]  E. Svandova,et al.  Six years' experience with the discontinuation of BCG vaccination , 1993 .

[5]  T. Kanauchi,et al.  Prognostic factors of 634 HIV-negative patients with Mycobacterium avium complex lung disease. , 2012, American journal of respiratory and critical care medicine.

[6]  S. Holland,et al.  Prevalence of nontuberculous mycobacterial lung disease in U.S. Medicare beneficiaries. , 2012, American journal of respiratory and critical care medicine.

[7]  K. Winthrop,et al.  Pulmonary nontuberculous mycobacterial disease prevalence and clinical features: an emerging public health disease. , 2010, American journal of respiratory and critical care medicine.

[8]  T. Marras,et al.  Isolation prevalence of pulmonary nontuberculous mycobacteria in Ontario in 2007. , 2011, Canadian respiratory journal.

[9]  Mary Ann Blosky,et al.  Nontuberculous mycobacterial lung disease prevalence at four integrated health care delivery systems. , 2010, American journal of respiratory and critical care medicine.

[10]  T. Marras,et al.  Isolation prevalence of pulmonary non-tuberculous mycobacteria in Ontario, 1997–2003 , 2007, Thorax.

[11]  H. Sørensen,et al.  Nontuberculous pulmonary mycobacteriosis in Denmark: incidence and prognostic factors. , 2010, American journal of respiratory and critical care medicine.

[12]  E. Svandova,et al.  Six years' experience with the discontinuation of BCG vaccination. 4. Protective effect of BCG vaccination against the Mycobacterium avium intracellulare complex. , 1994, Tubercle and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[13]  S. Field,et al.  Mycobacterium avium complex pulmonary disease in patients without HIV infection. , 2004, Chest.

[14]  H. Hallander,et al.  Atypical mycobacteria in extrapulmonary disease among children. Incidence in Sweden from 1969 to 1990, related to changing BCG-vaccination coverage. , 1995, Tubercle and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[15]  Yoshihiro Kobashi,et al.  The Microbiological and Clinical Effects of Combined Therapy according to Guidelines on the Treatment of Pulmonary Mycobacterium avium Complex Disease in Japan – Including a Follow-Up Study , 2006, Respiration.

[16]  P. Kao,et al.  Mycobacterium avium-intracellulare pulmonary infection in HIV-negative patients without preexisting lung disease: diagnostic and management limitations. , 1999, Chest.

[17]  T. Marras,et al.  Aging, COPD, and other risk factors do not explain the increased prevalence of pulmonary Mycobacterium avium complex in Ontario. , 2012, Chest.

[18]  N. Ampel.  Diagnosis, Treatment, and Prevention of Nontuberculous Mycobacterial Diseases , 2007 .